Q4 earnings of $2.16 per share, and revenues of $15.1bn surpassed Wall Street's expectations, while across the year as a whole, net revenues of $56.3bn beat ... small cell lung cancer, but the ...

John Ryan, a U.S. Navy veteran, beat cancer through nearly a decade of experimental immunotherapy treatment. The vet shared ...

Lung cancer remains a leading cause of cancer death globally, with a significant rise in cases among non-smokers attributed to air pollution, according to a recent WHO study. The study highlights ...

Lung cancer is the second most diagnosed cancer in the United States. The American Cancer Society estimates around 226,650 new cases of lung cancer in 2025. Small cell makes up around 15% of all ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...

Lung cancer screening aims to find lung cancer early. This is when there are more treatment options available and there is the best chance of treating it successfully. In the UK, the National ...

To mark World Cancer Day, Professor Caroline Dive from Cancer Research UK’s Lung Cancer Centre of Excellence explains how a £4m funding boost from ScottishPower is supercharging incredible ...

Lung cancer, one of the four most common types of cancer in the UK, sees over 49,000 new cases each year, according to Cancer Research UK. This disease is triggered by an uncontrolled growth of ...

These changes lead to frequent inflammation ... Feb. 6, 2025 — Scientists have created a new low-cost, fast response sensor to detect lung cancer biomarkers, paving the way for the development ...

This is less common in lung NETs compared to NETs that start in the digestive system. The hormones can cause symptoms that can seem separate to the cancer. These symptoms include: skin flushing ...

Tuesday, Feb. 4 is World Cancer Day. The annual observation is marked to help raise awareness, educate and celebrate gains ...

Last week’s NICE rejection of Opdivo for routine use in lung cancer patients has presented BMS with another setback – and an opportunity for Merck Sharp & Dohme (Merck in the US) and its rival ...